Table 1 Clinical details and pathological characteristics of tumor specimens used for generating the PDX WHIM lines, as determined and further described in a previous publication [11]
| Â | Â | Patient details | Â | Â | Xenograft details | ||||
|---|---|---|---|---|---|---|---|---|---|
Pt ID | Receptor status | Subtype | Source of tissue | Sites of metastasis | Survival (months) | WHIM line | Mouse ID | Receptor status | Site of metastases |
262 | ER+/HER2- | Luminal-B | Breast | BN, CNS | 37 | 11 | 11E 1221 | ER+/HER2- | None |
303 | ER-/HER2- | Claudin-low | Breast | PL, PC | 12 | 12 | 12A 1282 | ER-/HER2- | L |
12A1291 | L | ||||||||
12C1363 | ER-/HER2- | H | |||||||
12C1264 | None | ||||||||
12C 1375 | None | ||||||||
12C 1376 | None | ||||||||
270 | ER-/HER2- | Basal | Chest wall | BR, CT, L, H, BN | 44+ b | 13 | 13A 1204 | ER-/PR- | None |
7192 | ER-/HER2- | Claudin-low | Breast | None | 37+ b | 17 | 17A 1384 | ER-/HER2- | H, N |
17B 1139 | ER-/HER2- | H | |||||||
17B 1141 | L | ||||||||
17B1188 | L, H | ||||||||
17B29 | L, H, S | ||||||||
17C1180 | ER-/HER2- | L | |||||||
17C1182 | L, H, S, K | ||||||||
319 | ER+/HER2- | Luminal-B | Skin | CT, N | 97 | 23 | 23C 1832 | Â | None |
23C 1833 | ER+/HER2- | None | |||||||
23C 1834 | Â | None | |||||||